Athira Pharma’s stock price fell 81% as its lead fosgonimeton treatment for Alzheimer’s disease failed its phase II/III LIFT-AD clinical trial. The drug did not meet the trial’s primary or key secondary endpoints. However, chief medical officer Javier San Martin said Athira planned to continue developing fosgonimeton, citing preliminary results from various subgroups.
MacOS Malware Poses as Unarchiver App to Steal User Data
Well, cyber friends! You won’t believe what we just uncovered on our daily hunt for all things security-related here at the Bay Area cyberhawks HQ.